BioSpace News Archive

Genprex, Inc. today announced that the Safety Review Committee (SRC) has approved continuation of the Acclaim-1 Phase 1/2 clinical trial of REQORSA™ in combination with Tagrisso® (osimertinib) to treat late-stage non-small cell lung cancer (NSCLC) following a review of the first cohort of patients in the Phase 1 portion of the trial.

Halozyme Therapeutics, Inc. today announced that it intends to offer, subject to market conditions and other factors, $500 million aggregate principal amount of convertible senior notes due 2028 (the “Convertible Notes”).

ABVC BioPharma, Inc. (Nasdaq: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced its financial and operating results for the second quarter of 2022.

Gannex Pharma Co., Ltd. (“Gannex”), a wholly owned company of Ascletis Pharma Inc. (HKEX: 1672) today announces that it has completed the first subject dosing in the U.S. drug-drug interaction (DDI) study of Farnesoid X receptor (FXR) agonist ASC42 for treatment of primary biliary cholangitis (PBC).

TELA Bio, Inc. announced the pricing of its previously announced underwritten public offering of 4,000,000 shares of its common stock at a price to the public of $8.00 per share, for gross proceeds of $32.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses.

Elite Pharmaceuticals, Inc., a specialty pharmaceutical company developing niche generic products, announced results for the first quarter of fiscal year 2023 ended June 30, 2022.

(La Jolla, CA USA) The world is experiencing a crisis in prescription drug abuse and overdose.

Toragen, Inc., a San Diego-based biotechnology company focused on developing, repurposing and commercializing uniquely selective drugs targeting cancers caused by the human papillomavirus, announced the appointment of Mr. Paul Engler, of Amarillo, Texas, to the Board of Directors of the Company.

Cullinan Oncology, Inc., a biopharmaceutical company focused on developing a diversified pipeline of targeted therapeutic candidates across multiple modalities for patients with cancer, announced that Jacquelyn Sumer, J.D., will join the company as Chief Legal Officer.

The second quarter of 2022 was an exciting one for Zomedica as we both grew revenue organically and also executed on our acquisition strategy. We were pleased with our revenue growth to $4.2 million which reflects a 51% increase on a pro-forma basis, over the combined revenue of Zomedica and PulseVet as a standalone company of $2.8 million in the second quarter of last year.